X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 44.5 12.2 364.4% View Chart
P/BV x 11.1 3.2 344.5% View Chart
Dividend Yield % 0.6 0.4 161.4%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
GLENMARK PHARMA
Mar-17
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,015993 605.7%   
Low Rs3,707729 508.3%   
Sales per share (Unadj.) Rs1,236.9325.5 380.0%  
Earnings per share (Unadj.) Rs122.239.3 310.9%  
Cash flow per share (Unadj.) Rs129.048.7 265.0%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %0.70.2 310.0%  
Book value per share (Unadj.) Rs521.2159.2 327.4%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.92.6 148.6%   
Avg P/E ratio x39.821.9 181.5%  
P/CF ratio (eoy) x37.717.7 213.0%  
Price / Book Value ratio x9.35.4 172.4%  
Dividend payout %28.65.1 562.8%   
Avg Mkt Cap Rs m103,296242,991 42.5%   
No. of employees `0003.013.0 22.8%   
Total wages/salary Rs m3,37016,408 20.5%   
Avg. sales/employee Rs Th8,891.87,083.9 125.5%   
Avg. wages/employee Rs Th1,140.01,265.4 90.1%   
Avg. net profit/employee Rs Th878.3855.1 102.7%   
INCOME DATA
Net Sales Rs m26,28491,857 28.6%  
Other income Rs m504374 135.0%   
Total revenues Rs m26,78992,230 29.0%   
Gross profit Rs m3,66520,367 18.0%  
Depreciation Rs m1442,644 5.5%   
Interest Rs m82,373 0.3%   
Profit before tax Rs m4,01715,724 25.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,4213,827 37.1%   
Profit after tax Rs m2,59611,088 23.4%  
Gross profit margin %13.922.2 62.9%  
Effective tax rate %35.424.3 145.3%   
Net profit margin %9.912.1 81.8%  
BALANCE SHEET DATA
Current assets Rs m14,44668,746 21.0%   
Current liabilities Rs m4,72527,027 17.5%   
Net working cap to sales %37.045.4 81.4%  
Current ratio x3.12.5 120.2%  
Inventory Days Days5185 60.5%  
Debtors Days Days2096 20.5%  
Net fixed assets Rs m1,11324,132 4.6%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m10,80844,643 24.2%   
Net worth Rs m11,07644,925 24.7%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m16,241117,639 13.8%  
Interest coverage x497.07.6 6,517.1%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.60.8 207.3%   
Return on assets %16.011.4 140.1%  
Return on equity %23.424.7 95.0%  
Return on capital %36.319.1 189.8%  
Exports to sales %0.60-   
Imports to sales %12.60-   
Exports (fob) Rs m162NA-   
Imports (cif) Rs m3,322NA-   
Fx inflow Rs m26856,152 0.5%   
Fx outflow Rs m3,9278,084 48.6%   
Net fx Rs m-3,65948,068 -7.6%   
CASH FLOW
From Operations Rs m2,5146,574 38.2%  
From Investments Rs m-800-7,124 11.2%  
From Financial Activity Rs m-8035,432 -14.8%  
Net Cashflow Rs m9121,992 45.8%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS